LXN
Overview
LXN (Latexin) encodes the only known endogenous carboxypeptidase inhibitor in mammals. In muscle-invasive bladder cancer (MIBC), LXN was identified as epigenetically silenced through integrated DNA methylation and gene expression analysis, nominating it as a candidate tumor suppressor inactivated by promoter hypermethylation in bladder cancer.
Alterations observed in the corpus
- LXN was epigenetically silenced in 27% of muscle-invasive bladder cancer (MIBC) tumors (n=412) by promoter DNA hypermethylation and concordant loss of expression, identified as part of a set of 158 epigenetically silenced genes by integrated methylation-expression analysis PMID:28988769
Cancer types (linked)
- BLCA (Bladder Urothelial Carcinoma): LXN silenced in 27% of MIBC tumors by promoter hypermethylation; epigenetic silencing was identified as the sole inactivation mechanism, as LXN was not among the genes with somatic mutations PMID:28988769
Co-occurrence and mutual exclusivity
Therapeutic relevance
- Epigenetic silencing of LXN suggests potential sensitivity to demethylating agents; no specific targeted therapy is reported in the corpus.
Open questions
- The functional consequences of LXN silencing in bladder cancer, and its relationship to specific molecular subtypes (luminal vs. basal-squamous), remain to be defined.
Sources
This page was processed by crosslinker on 2026-05-15.